Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q3

6523.TEDINET S100Q6BS
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥265.1bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥94.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥340.5bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥252.4bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥86.3bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥21.4bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥10.9bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥24.1bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥10.5bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥7.4bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥4.0bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥3.0bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥24.9bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥4.8bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥3.4bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥8.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥18.5bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.5bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥3.6bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥2.2bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥18.6bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥3.6bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥569.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥591.3bnat 2022-03-31Cons.Assets IFRS
Total assets¥595.1bnat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥431.1bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥455.3bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥138.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥152.1bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥107.6bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥137.9bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥135.4bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥151.5bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥59.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.0bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥6.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥51.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥36.0bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥11.3bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥12.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥9.4bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥32.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥7.0bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥106m2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥27.332022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.692022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥-70.782021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥156.672021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥28.832021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥27.072022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.532022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-70.782021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥152.822021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥28.342021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio24.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio22.9%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio25.5%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31¥1.8bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥1.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥13.0bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-12-31¥83.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-12-31¥83.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-12-31¥19.7bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-12-31¥80.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-12-31¥80.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.3bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-12-31¥99.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-12-31¥99.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-12-31¥8.5bn
—segment totalrevenue2022-04-01 → 2022-12-31¥263.3bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥263.3bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥34.4bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31¥2.1bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-12-31¥2.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥11.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue2021-04-01 → 2021-12-31¥82.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue external2021-04-01 → 2021-12-31¥82.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentsegment profit2021-04-01 → 2021-12-31¥18.7bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2021-04-01 → 2021-12-31¥68.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2021-04-01 → 2021-12-31¥68.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.6bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue2021-04-01 → 2021-12-31¥99.6bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue external2021-04-01 → 2021-12-31¥99.6bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentsegment profit2021-04-01 → 2021-12-31¥12.4bn
—segment totalrevenue2021-04-01 → 2021-12-31¥250.3bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥250.3bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥35.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 934
ItemContextValueUnit
Forfeiture of share acquisition rights and restricted stock unit ss IFRSCurrentYTDDuration-3000000JPY
Share based payment transactions ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember261000000JPY
Share based payment transactions ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration261000000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-822000000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration－JPY
Other ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Other ss IFRSCurrentYTDDuration_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember－JPY
Other ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Other ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-0JPY
Other ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember13000000JPY
Other ss IFRSCurrentYTDDuration12000000JPY
Total transactions with owners IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Total transactions with owners IFRSCurrentYTDDuration_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember－JPY
Total transactions with owners IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-822000000JPY
Total transactions with owners IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-8719000000JPY
Total transactions with owners IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-99000000JPY
Total transactions with owners IFRSCurrentYTDDuration-8818000000JPY
Equity IFRSCurrentQuarterInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember22460000000JPY
Equity IFRSCurrentQuarterInstant_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember626000000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember23471000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember137947000000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember839000000JPY
Equity IFRSCurrentQuarterInstant138786000000JPY
Profit loss before tax IFRSPrior1YTDDuration24907000000JPY
Profit loss before tax IFRSCurrentYTDDuration7414000000JPY
Depreciation expense ope cf IFRSPrior1YTDDuration23469000000JPY
Depreciation expense ope cf IFRSCurrentYTDDuration22250000000JPY
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration-98000000JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration375000000JPY
Gain loss from financial assets measured at fair value through profit or loss ope cf IFRSPrior1YTDDuration-3020000000JPY
Gain loss from financial assets measured at fair value through profit or loss ope cf IFRSCurrentYTDDuration6405000000JPY
Interest expenses ope cf IFRSPrior1YTDDuration2012000000JPY
Interest expenses ope cf IFRSCurrentYTDDuration4926000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration203000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration264000000JPY
Loss gain on sale of fixed assets ope cf IFRSPrior1YTDDuration-26000000JPY
Loss gain on sale of fixed assets ope cf IFRSCurrentYTDDuration-17000000JPY
Decrease increase in trade receivables ope cf IFRSPrior1YTDDuration3982000000JPY
Decrease increase in trade receivables ope cf IFRSCurrentYTDDuration-885000000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-5030000000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-6068000000JPY
Increase decrease in trade payables ope cf IFRSPrior1YTDDuration-2476000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass